Abstract

Lung cancer (LC) accounts for 1.6 million death each year, remaining the leading cause of oncology-related death. This worst-case scenario is linked to poor survival associated with late diagnosis. This happens commonly in clinical practice, even in countries with strong and developed health systems, resulting in a lower chance of survival and a higher cost of treatment. Ideally, screening in an asymptomatic at-risk population could increase the chance of recognition cancerous cells, or even pre-cancerous conditions, in a majority of individuals who will results negative to the test. With this article, we aim to summarize the best new approach in LC research.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.